These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 36958825)

  • 1. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
    Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
    Tob Control; 2023 Mar; ():. PubMed ID: 36958825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Landscape of Cigar Marketing in Print Magazines from 2018-2021: Content, Expenditures, Volume, Placement and Reach.
    Ganz O; Wackowski OA; Gratale S; Chen-Sankey J; Safi Z; Delnevo CD
    Int J Environ Res Public Health; 2022 Dec; 19(23):. PubMed ID: 36498246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups.
    Khayat A; Berg CJ; Levine H; Rodnay M; Abroms L; Romm KF; Duan Z; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e54-e61. PubMed ID: 36418166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
    Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
    Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do Young Adults Attend to Health Warnings in the First IQOS Advertisement in the U.S.? An Eye-Tracking Approach.
    Liu J; Phua J; Krugman D; Xu L; Nowak G; Popova L
    Nicotine Tob Res; 2021 May; 23(5):815-822. PubMed ID: 33245339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure to IQOS ads and reduced exposure claims, and association with perceived risk from COVID-19 on IQOS purchase and use intentions: results from a web-based survey.
    Sharma A; Fix B; Hyland A; Bansal-Travers M; Quisenberry A; O'Connor R
    Front Public Health; 2023; 11():1307484. PubMed ID: 38269390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magazine hyped: Trends in tobacco advertising and readership characteristics, 2010-2014.
    El-Toukhy SM; Choi K
    Prev Med; 2016 Oct; 91():132-137. PubMed ID: 27519170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of different health warning label and reduced exposure messages in IQOS ads on perceptions among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Abroms LC; Khayat A; Romm KF; Levine H; Bar-Zeev Y
    Prev Med Rep; 2023 Jun; 33():102209. PubMed ID: 37223575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral nicotine product marketing expenditures in the USA from 2016 to 2023: trends over time by brand and targeted media outlets.
    Ozga JE; Cornacchione Ross J; Hrywna M; Sharma A; Ling PM; Stanton CA
    Tob Control; 2024 Mar; ():. PubMed ID: 38485232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.
    Khayat A; Levine H; Berg CJ; Shauly-Aharonov M; Manor O; Abroms L; Romm KF; Wysota CN; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e3-e10. PubMed ID: 36368887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine Delivery of a Menthol-Flavored Heat-not-Burn Tobacco Product During Directed Use.
    Yingst JM; Bordner C; Hrabovsky S; Hobkirk AL; Trushin N; Richie JP; Foulds J
    Nicotine Tob Res; 2024 Feb; 26(3):397-401. PubMed ID: 37434562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticipating IQOS market expansion in the United States.
    Abroms L; Levine H; Romm K; Wysota C; Broniatowski D; Bar-Zeev Y; Berg C
    Tob Prev Cessat; 2022; 8():04. PubMed ID: 35174298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IQOS news media coverage in Israel: a comparison across three subpopulations.
    Khayat A; Bar-Zeev Y; Kaufman Y; Berg C; Abroms L; Duan Z; LoParco CR; Wang Y; Cui Y; Levine H
    Tob Control; 2024 Jul; ():. PubMed ID: 39013604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inferences beyond a claim: a typology of potential halo effects related to modified risk tobacco product claims.
    Seidenberg AB; Popova L; Ashley DL; Wackowski OA
    Tob Control; 2020 Oct; ():. PubMed ID: 33046582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.